The FDA just approved the first gene editing therapy for sickle cell anemia, but it'll cost $2.2 million per person

• The FDA approved the first gene therapies for sickle cell anemia.
• The two approved treatments, Casgevy and Lyfgenia, will cost $2.2 million and $3.1 million.
• Casgevy is the first therapy to use the CRISPR gene editing tool that won the Nobel Prize.

The FDA approved the first gene therapy treatments for sickle cell disease on Friday, but it will cost patients millions of dollars.